Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HK A+H IPO 2025: Essential Statistics Ahead of the 2026 Wave

HK A+H IPO 2025 Cornerstone Lock-Up Expiry: Price and Liquidity Evidences

HK A+H IPO 2026: Performance Drivers, Premium Dynamics, and 2W Return Attribution

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Duality Biotherapeutics / Equity Capital Markets

<ul>
<li>In this note, we take a statistical view of the Biotech listing in 2025.</li>
<li>We illustrate the time series of IPO performance, subscription, and market sentiment, as well as the performances for sponsors.</li>
<li>Lastly, we provide a breakdown of performance by therapeutic areas.</li>
</ul>


In this note, we take a statistical view of the Biotech listing in 2025.
We illustrate the time series of IPO performance, subscription, and market sentiment, as well as the performances for sponsors.
Lastly, we provide a breakdown of performance by therapeutic areas.


HK Biotech IPO 2025: A Statistical Review